Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Linaclotide 290 micrograms, Matching placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 111
States / cities: Birmingham, Alabama • Hueytown, Alabama • Huntsville, Alabama + 94 more

Conditions: Tourette Syndrome
Interventions: TEV-50717, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Safety and Pharmacokinetics of Intravenous Baclofen
Interventions: Intravenous baclofen; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions: BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN; Drug
Lead sponsor: Gauda, Estelle B., M.D.; Individual
Eligibility: Up to 7 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more

Conditions: Substance Withdrawal Syndrome
Interventions: Melatonin, Matched Placebo; Dietary Supplement
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
Interventions: Buspirone oral capsule, Placebo oral capsule; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fragile X Syndrome
Interventions: arbaclofen, Placebo; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Nurse's Role, Stigma, Social, Implicit Bias
Interventions: ArtSpective; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Saint Cloud, Minnesota • Toledo, Ohio

Conditions: Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions: Buprenorphine, Morphine Sulfate; Drug
Lead sponsor: Pediatrix; Other
Eligibility: Up to 1 Year
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Dexmedetomidine, Placebos; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 89 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more

Conditions: Neonatal Opioid Withdrawal Syndrome
Interventions: Buprenorphine or Placebo, Morphine or Placebo; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Opioid Withdrawal
Interventions: Lofexidine; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 18
States / cities: Little Rock, Arkansas • Springdale, Arkansas • San Diego, California + 15 more

Conditions: Substance Withdrawal Syndrome
Interventions: dehydroepiandrosterone (DHEA), pregnenolone, Placebo; Dietary Supplement · Drug
Lead sponsor: Jed E. Rose; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions: Lofexidine HCl, Lofexidine-matching sugar pill; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neonatal Opioid Withdrawal Syndrome
Interventions: CHF6563, Morphine, CHF6563 matched placebo, Morphine matched placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: Up to 7 Days
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Las Vegas, Nevada • Philadelphia, Pennsylvania

Conditions: Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Interventions: Continuous 3,4-DAP, Taper 3,4-DAP to Placebo; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 7
States / cities: Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more

Conditions: Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue, Autoimmune Enteropathy
Interventions: Withdrawal of Oral Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Substance Withdrawal Syndrome
Interventions: Olanzapine, Clonidine; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions: Withdrawal of immunosuppression and donor lymphocyte infusion; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Months to 25 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: San Francisco, California • St. Petersburg, Florida

Conditions: Withdrawal Symptoms
Interventions: Oxycodone/Naltrexone Capsules, Oxycodone, Placebo; Drug
Lead sponsor: Elite Laboratories, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions: Buprenorphine Injection, Buprenorphine Sublingual Product; Drug
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years to 41 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more

Search by objective public record fields.

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program

Buspirone for Opioid Tapering

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Testing an Arts-based Program to Reduce Nurse Stigma Towards Perinatal Substance Use

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)

Open-Label, Safety Study of Lofexidine

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Budesonide in Patients With Immune Mediated Enteropathies

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study